Back

Environmental impact analysis of ajmaline challenge protocols: a comparative assessment of carbon footprint reduction in Brugada Syndrome diagnosis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Insights into cardiovascular health: trends, well-being, and economic evaluations Public Health ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Catia Oliveira

Sao Joao Hospital, Porto (Portugal)

7 More presentations in this session

Presentation thumbnail
Nationwide trends in major cardiovascular risk factors in England in the last 2 decades: Health Survey of England 2003-2019
Doctor C. Graham (London, GB)
Abstract Slides Video
Presentation thumbnail
The health and wellbeing of cardiology trainees in the united kingdom
Doctor W. Jenner (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Association between wearable activity trackers usage and levels of physical activity among Athens Medical Society members
Doctor E. Oikonomou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Economic evaluation of fractional flow reserve-guided versus intravascular ultrasound-guided percutaneous coronary intervention
Doctor X. Hu (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Prevecardio: a single-visit population screening model for detection and prevention of 10-year cardiovascular risk
Doctor J. Flores Soler (Madrid, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Insights into cardiovascular health: trends, well-being, and economic evaluations

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Small changes can make a difference: the impact of different ajmaline challenge protocols on carbon footprint
thumbnail
Congress Presentation
Ajmaline testing in Brugada Syndrome: a comparative analysis of diagnostic protocols and clinical outcomes across two hospital centers
thumbnail
Congress Presentation
Carbon emission reduction associated with dapagliflozin compared to standard of care in the UK: translating the DAPA-HF and DELIVER trial findings to an environmental context

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources